CN113307741B - 一种屈昔多巴的制备方法 - Google Patents
一种屈昔多巴的制备方法 Download PDFInfo
- Publication number
- CN113307741B CN113307741B CN202010118851.1A CN202010118851A CN113307741B CN 113307741 B CN113307741 B CN 113307741B CN 202010118851 A CN202010118851 A CN 202010118851A CN 113307741 B CN113307741 B CN 113307741B
- Authority
- CN
- China
- Prior art keywords
- compound
- droxidopa
- qub08
- formula
- weak base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229960001104 droxidopa Drugs 0.000 title abstract description 22
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 claims abstract description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- 238000006243 chemical reaction Methods 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 29
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 12
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 abstract description 18
- 239000012535 impurity Substances 0.000 abstract description 12
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 abstract description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 9
- 239000002245 particle Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 44
- 238000012216 screening Methods 0.000 description 32
- 239000000203 mixture Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- 239000007787 solid Substances 0.000 description 24
- 239000008213 purified water Substances 0.000 description 22
- 238000002425 crystallisation Methods 0.000 description 20
- 230000008025 crystallization Effects 0.000 description 20
- QXWYKJLNLSIPIN-JGVFFNPUSA-N droxidopa Chemical compound OC(=O)[C@@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JGVFFNPUSA-N 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 239000012065 filter cake Substances 0.000 description 13
- 238000013401 experimental design Methods 0.000 description 11
- 239000003513 alkali Substances 0.000 description 8
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 150000003354 serine derivatives Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- XDDLXZHBWVFPRG-UHFFFAOYSA-N 3,4-bis(phenylmethoxy)benzaldehyde Chemical compound C=1C=CC=CC=1COC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 XDDLXZHBWVFPRG-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 1
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010118851.1A CN113307741B (zh) | 2020-02-26 | 2020-02-26 | 一种屈昔多巴的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010118851.1A CN113307741B (zh) | 2020-02-26 | 2020-02-26 | 一种屈昔多巴的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113307741A CN113307741A (zh) | 2021-08-27 |
CN113307741B true CN113307741B (zh) | 2024-05-14 |
Family
ID=77370116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010118851.1A Active CN113307741B (zh) | 2020-02-26 | 2020-02-26 | 一种屈昔多巴的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113307741B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6422849A (en) * | 1987-07-16 | 1989-01-25 | Sumitomo Pharma | Purification of 3-(3,4-dihydroxyphenyl)serine |
JP2005204644A (ja) * | 2004-01-20 | 2005-08-04 | Miat Spa | (−)−(2s,3r)−2−アミノ−3−ヒドロキシ−3−フェニルプロピオン酸誘導体の製法 |
CN103086906A (zh) * | 2011-11-03 | 2013-05-08 | 重庆圣华曦药业股份有限公司 | 屈昔多巴的晶型及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9920342B2 (en) * | 2016-05-17 | 2018-03-20 | Divi's Laboratories Limited | Process for the preparation of Droxidopa |
-
2020
- 2020-02-26 CN CN202010118851.1A patent/CN113307741B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6422849A (en) * | 1987-07-16 | 1989-01-25 | Sumitomo Pharma | Purification of 3-(3,4-dihydroxyphenyl)serine |
JP2005204644A (ja) * | 2004-01-20 | 2005-08-04 | Miat Spa | (−)−(2s,3r)−2−アミノ−3−ヒドロキシ−3−フェニルプロピオン酸誘導体の製法 |
CN103086906A (zh) * | 2011-11-03 | 2013-05-08 | 重庆圣华曦药业股份有限公司 | 屈昔多巴的晶型及其制备方法 |
Non-Patent Citations (1)
Title |
---|
屈昔多巴的合成;李鸿波;王立平;梁伍;陈凯;刘浪;;合成化学;18(01);第124-127页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113307741A (zh) | 2021-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4254053A (en) | Process for manufacturing D camphorate of L carnitinamide and D camphorate of D carnitinamide | |
JP2012519677A (ja) | シナカルセト及びその塩の製造方法、並びに該方法に使用する中間体 | |
CZ295098A3 (cs) | Nová asymetrická syntéza R-alfa-propylpiperonylaminu a jeho analogů | |
CN111170878B (zh) | 一种制备d-型或l-型叔亮氨酸的方法 | |
CN113307741B (zh) | 一种屈昔多巴的制备方法 | |
CN111039852A (zh) | N-乙基吡啶甲胺盐酸盐晶体、制备工艺及其在制备托品酰胺中的应用 | |
CN114516866B (zh) | 一种手性4-烷基-吡咯-3-甲酸类化合物的制备方法 | |
EA022300B1 (ru) | Разделение энантиомеров 2-амино-3,6-дигидро-4-диметиламино-6-метил-1,3,5-триазина с использованием винной кислоты | |
US11149003B2 (en) | Resolution of racemic beta-aminosulfone compounds | |
CN101973909A (zh) | 一种米屈肼的制备方法 | |
CN112830879A (zh) | 一种盐酸西那卡塞的制备方法 | |
CN114181117A (zh) | 一种帕拉米韦中间体的制备方法 | |
CN110759933A (zh) | 一种头孢地尼杂质g的制备方法 | |
EP2805936A1 (en) | Process for preparing levomilnacipran HCL | |
CN112375031B (zh) | 一种西尼地平的制备方法 | |
CN110835319B (zh) | 一种贝那普利中间体和贝那普利盐酸盐的合成方法 | |
US3988320A (en) | Single stage resolution/racemization of α-amino-ε-caprolactam | |
EP1341762A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
CN112608286B (zh) | 一种高纯度普拉克索的制备方法 | |
CN115181093B (zh) | Sunvozertinib中间体的制备方法 | |
CN113816917B (zh) | 一种维贝格龙中间体的制备方法 | |
EP1489066B1 (en) | Process for production of optically active carboxylic acid | |
CN101506146B (zh) | 3-氨基-5-氟-4-二烷氧基戊酸酯的制备方法 | |
JP4873207B2 (ja) | 光学活性カルボン酸クロリドの精製方法 | |
EP1142864A1 (en) | Process for producing l-erythro-(1r,2s)-2-amino-1-phenylpropan-1-ol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 103, building 21, No. 368, middle Zhen'an Road, Chang'an Town, Dongguan City, Guangdong Province 523871 Applicant after: Dongguan dongyangguang generic research and Development Co.,Ltd. Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: Room 103, building 21, No. 368, middle Zhen'an Road, Chang'an Town, Dongguan City, Guangdong Province 523871 Applicant before: Dongguan dongyangguang generic research and Development Co.,Ltd. Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |